NASDAQ:PRVB - Provention Bio Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $18.33
  • Forecasted Upside: 226.22 %
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$5.62
▲ +0.34 (6.44%)

This chart shows the closing price for PRVB by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Provention Bio Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PRVB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PRVB

Analyst Price Target is $18.33
▲ +226.22% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Provention Bio in the last 3 months. The average price target is $18.33, with a high forecast of $21.00 and a low forecast of $16.00. The average price target represents a 226.22% upside from the last price of $5.62.

This chart shows the closing price for PRVB for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 6 investment analysts is to buy stock in Provention Bio. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/18/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/19/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/17/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/15/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/13/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/14/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/13/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/12/2022

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/5/2022Chardan CapitalLower Price TargetBuy$22.50 ➝ $21.00Low
7/11/2022HC WainwrightLower Price TargetBuy$25.00 ➝ $18.00N/A
4/1/2022Cantor FitzgeraldReiterated RatingOverweightN/A
1/31/2022HC WainwrightReiterated RatingBuy$25.00High
11/23/2021Sumitomo Mitsui Financial GroupUpgradeNeutral ➝ OutperformHigh
11/23/2021UBS GroupUpgradeNeutral ➝ OutperformMedium
9/20/2021SVB LeerinkReiterated RatingBuy$16.00High
9/14/2021HC WainwrightReiterated RatingBuy$25.00High
8/6/2021HC WainwrightLower Price TargetBuy$27.00 ➝ $25.00High
8/6/2021OppenheimerLower Price TargetOutperform$18.00 ➝ $16.00High
7/11/2021Royal Bank of CanadaReiterated RatingHold$8.00Low
7/7/2021HC WainwrightReiterated RatingBuy$27.00Medium
7/1/2021Chardan CapitalReiterated RatingBuyMedium
5/31/2021SVB LeerinkReiterated RatingBuy$16.00Low
5/28/2021Chardan CapitalLower Price TargetBuy$35.00 ➝ $22.50High
5/28/2021OppenheimerReiterated RatingBuy$18.00High
5/7/2021Cantor FitzgeraldLower Price TargetOverweight$25.00 ➝ $19.00Medium
5/7/2021OppenheimerReiterated RatingBuy$18.00Medium
4/28/2021HC WainwrightReiterated RatingBuy$27.00High
4/19/2021HC WainwrightReiterated RatingBuy$34.00 ➝ $27.00Low
4/15/2021Royal Bank of CanadaReiterated RatingOutperform ➝ Sector Perform$25.00 ➝ $10.00Low
4/12/2021Chardan CapitalLower Price TargetBuy$35.00 ➝ $22.50Low
4/12/2021HC WainwrightLower Price TargetBuy$34.00 ➝ $27.00High
4/9/2021SVB LeerinkLower Price TargetOutperform$26.00 ➝ $16.00High
4/9/2021OppenheimerReiterated RatingBuy$18.00High
4/9/2021Cantor FitzgeraldLower Price TargetOverweight$27.00 ➝ $25.00High
4/9/2021Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$27.00 ➝ $25.00High
2/25/2021Chardan CapitalLower Price TargetBuy$40.00 ➝ $35.00High
2/22/2021HC WainwrightBoost Price TargetBuy$26.00 ➝ $34.00High
1/4/2021Chardan CapitalBoost Price TargetPositive ➝ Buy$35.00 ➝ $40.00N/A
11/3/2020Chardan CapitalReiterated RatingBuy$35.00Medium
10/2/2020HC WainwrightReiterated RatingBuy$26.00Medium
9/23/2020OppenheimerReiterated RatingBuy$29.00High
8/18/2020Royal Bank of CanadaReiterated RatingBuyLow
7/14/2020OppenheimerInitiated CoverageBuy$29.00Low
7/2/2020HC WainwrightReiterated RatingBuy$26.00N/A
6/16/2020Chardan CapitalBoost Price TargetBuy$30.00 ➝ $40.00Medium
6/16/2020HC WainwrightBoost Price TargetBuy$20.00 ➝ $26.00High
6/15/2020OppenheimerInitiated CoverageBuy$29.00High
6/4/2020Royal Bank of CanadaInitiated CoverageOutperform$25.00Low
6/3/2020OppenheimerInitiated CoverageOutperform$29.00Low
5/8/2020HC WainwrightReiterated RatingBuy$20.00High
4/17/2020HC WainwrightReiterated RatingBuy$20.00High
4/1/2020Chardan CapitalBoost Price TargetBuy$18.50 ➝ $30.00Low
3/18/2020HC WainwrightReiterated RatingBuyHigh
1/24/2020Cantor FitzgeraldInitiated CoverageOverweight$25.00High
1/2/2020SVB LeerinkReiterated RatingOutperformLow
12/30/2019HC WainwrightReiterated RatingBuy$20.00High
12/13/2019HC WainwrightReiterated RatingBuy$20.00High
10/28/2019HC WainwrightReiterated RatingBuy$20.00Medium
10/23/2019Chardan CapitalReiterated RatingBuy$18.50Medium
9/19/2019Chardan CapitalReiterated RatingBuyMedium
8/5/2019SVB LeerinkBoost Price TargetOutperform$17.00 ➝ $35.00High
6/26/2019HC WainwrightReiterated RatingBuy ➝ Buy$8.00 ➝ $20.00High
6/10/2019Chardan CapitalInitiated CoverageBuy$20.00High
5/28/2019HC WainwrightSet Price TargetBuy$8.00Medium
4/25/2019HC WainwrightReiterated RatingBuy$8.00Low
2/22/2019SVB LeerinkInitiated CoverageOutperformLow
1/29/2019HC WainwrightReiterated RatingBuy$8.00High
1/18/2019HC WainwrightInitiated CoverageBuy$7.50High
(Data available from 8/12/2017 forward)

News Sentiment Rating

0.35 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/14/2022
  • 2 very positive mentions
  • 14 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
2/13/2022
  • 0 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
3/15/2022
  • 2 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/14/2022
  • 3 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/14/2022
  • 3 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
6/13/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/13/2022
  • 2 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/12/2022

Current Sentiment

  • 2 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Provention Bio logo
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease; and a strategic collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. to develop and commercialize PRV-3279, a bispecific antibody-based molecule targeting the B cell surface proteins CD32B and CD79B in Greater China. Provention Bio, Inc. was incorporated in 2016 and is headquartered in Red Bank, New Jersey.
Read More

Today's Range

Now: $5.62
Low: $5.33
High: $5.76

50 Day Range

MA: $4.14
Low: $3.43
High: $5.38

52 Week Range

Now: $5.62
Low: $3.18
High: $8.04

Volume

970,423 shs

Average Volume

764,424 shs

Market Capitalization

$359.90 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.45

Frequently Asked Questions

What sell-side analysts currently cover shares of Provention Bio?

The following Wall Street sell-side analysts have issued stock ratings on Provention Bio in the last twelve months: Cantor Fitzgerald, Chardan Capital, HC Wainwright, Sumitomo Mitsui Financial Group, Inc., SVB Leerink LLC, and UBS Group AG.
View the latest analyst ratings for PRVB.

What is the current price target for Provention Bio?

3 Wall Street analysts have set twelve-month price targets for Provention Bio in the last year. Their average twelve-month price target is $18.33, suggesting a possible upside of 226.2%. Chardan Capital has the highest price target set, predicting PRVB will reach $21.00 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $16.00 for Provention Bio in the next year.
View the latest price targets for PRVB.

What is the current consensus analyst rating for Provention Bio?

Provention Bio currently has 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PRVB will outperform the market and that investors should add to their positions of Provention Bio.
View the latest ratings for PRVB.

What other companies compete with Provention Bio?

How do I contact Provention Bio's investor relations team?

Provention Bio's physical mailing address is P.O. BOX 666, OLDWICK NJ, 08858. The company's listed phone number is (908) 428-9136 and its investor relations email address is [email protected] The official website for Provention Bio is www.proventionbio.com. Learn More about contacing Provention Bio investor relations.